Many new chemical entities struggle to progress into clinical development due to their physico-chemical properties and respective solubility and bioavailability challenges. APIs nanoformed using the CESS process have shown promise for overcoming this challenge by increasing the powder dissolution and even intrinsic solubility of the compounds.
This collaboration with Nanoform presents Orion an opportunity to enhance the company’s formulation process and provide poorly soluble molecules with a path to clinical trials.
“We are delighted to continue our relationship with Orion and we look forward to creating a successful partnership between our companies. Orion has a long and successful pharmaceutical history and is keen to evaluate new innovations. Together we look forward to combined success,” said Prof. Edward Hæggström, CEO of Nanoform.